EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advanced Glycation End-Products and Diabetic Neuropathy of the Retina

Toshiyuki Oshitari iD

International Journal of Molecular Sciences · 02.02.2023 · 24 (3) · 2927

DOI: 10.3390/ijms24032927 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.02.2023. Verfasst von Toshiyuki Oshitari. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, Chiba 260-8670, Japan. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Diabetic Neuropathies, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Science, Sports, and Culture of the Japanese Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic retinopathy is a tissue-specific neurovascular impairment of the retina in patients with both type 1 and type 2 diabetes. Several pathological factors are involved in the progressive impairment of the interdependence between cells that consist of the neurovascular units (NVUs). The advanced glycation end-products (AGEs) are one of the major pathological factors that cause the impairments of neurovascular coupling in diabetic retinopathy. Although the exact mechanisms for the toxicities of the AGEs in diabetic retinopathy have not been definitively determined, the AGE-receptor of the AGE (RAGE) axis, production of reactive oxygen species, inflammatory reactions, and the activation of the cell death pathways are associated with the impairment of the NVUs in diabetic retinopathy. More specifically, neuronal cell death is an irreversible change that is directly associated with vision reduction in diabetic patients. Thus, neuroprotective therapies must be established for diabetic retinopathy. The AGEs are one of the therapeutic targets to examine to ameliorate the pathological changes in the NVUs in diabetic retinopathy. This review focuses on the basic and pathological findings of AGE-induced neurovascular abnormalities and the potential therapeutic approaches, including the use of anti-glycated drugs to protect the AGE-induced impairments of the NVUs in diabetic retinopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyDiabetic NeuropathiesDiabetes Mellitus, Type 2HumansGlycation End Products, AdvancedMaillard ReactionRetinaReceptor for Advanced Glycation End Products

Stichwörter der Autor:innen

advanced glycation end-productsanti-glycationapoptosisdiabetic retinopathyneuroprotectionneurovascular unitnutrientsoxidative stresspolyol pathwayreceptor of AGEs

Substanzen

Glycation End Products, AdvancedReceptor for Advanced Glycation End Products

Autor:innen und Institutionen

  • Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, Chiba 260-8670, Japan.
  • Department of Ophthalmology, School of Medicine, International University of Health and Welfare, 4-3 Kozunomori, Narita 286-8686, Japan.

ORCID-Profile: Toshiyuki Oshitari

Förderung

  • Ministry of Education, Science, Sports, and Culture of the Japanese Government

Zitieren

APA

Oshitari, T. (2023). Advanced Glycation End-Products and Diabetic Neuropathy of the Retina. International Journal of Molecular Sciences, 24(3), 2927. https://doi.org/10.3390/ijms24032927

Vancouver

Oshitari T. Advanced Glycation End-Products and Diabetic Neuropathy of the Retina. International Journal of Molecular Sciences. 2023;24(3):2927. doi:10.3390/ijms24032927

BibTeX
@article{Oshitari2023,
  author = {Oshitari, Toshiyuki},
  title = {Advanced Glycation End-Products and Diabetic Neuropathy of the Retina},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {2927},
  doi = {10.3390/ijms24032927}
}
Kostenlos starten →